Vericel Lifts 2026 Outlook After Standout Quarter

Vericel Corporation ((VCEL)) has held its Q1 earnings call. Read on for the main highlights of the call.

Vericel Corporation’s latest earnings call struck an overwhelmingly upbeat tone, with management highlighting record revenue, accelerating growth in its core MACI franchise, and surging burn care sales. Executives emphasized stronger margins, rising cash generation and a sizable new BARDA award, while acknowledging that future BARDA revenue, conversion rates and macro conditions remain key swing factors.

Record Revenue and Strong YoY Growth

Vericel opened 2026 with a breakout quarter, posting total revenue of $68.4 million, up 30% year over year and comfortably ahead of guidance. Management framed the beat as evidence that demand is broad-based across the portfolio and that recent commercial investments are translating quickly into higher volumes.

MACI Outstanding Performance

MACI once again did the heavy lifting, generating $56.4 million in Q1 revenue, a 22% year-over-year increase and the fourth straight quarter of at least 20% growth. The trailing four-quarter growth rate ticked up to 23%, and guidance for the second quarter implies MACI revenue of about $62.5 million to $63.5 million, signaling management’s confidence in continued momentum.

Burn Care Momentum and BARDA Award

Burn Care revenue topped $12 million in the quarter, rising more than 90% from a year earlier on strong Epicel sales of $10.9 million and NexoBrid revenue of $1.1 million. The company also unveiled a BARDA award valued at up to $197 million, including a $35 million base contract and an expected $5 million to $6 million of NexoBrid procurement revenue in the second half of 2026.

Margin Expansion and Profitability Improvement

Profitability metrics moved sharply higher, with gross margin expanding by more than 300 basis points to 72% and adjusted EBITDA margin improving nearly 800 basis points to 14%. Adjusted EBITDA reached roughly $9.6 million, almost tripling from the prior year, underscoring improving operating leverage as revenue scales.

Strong Cash Generation and Balance Sheet

The company’s cash engine continued to strengthen, generating $16.4 million of operating cash flow and $15.1 million of free cash flow in the quarter, its third straight period with at least $12 million of free cash flow. Cash and investments climbed to about $211 million, nearly $50 million higher than a year earlier, giving Vericel ample financial flexibility.

Commercial Execution and Sales Force Expansion

Vericel’s expanded MACI sales force delivered immediate results, driving record levels of biopsies, implants and active surgeons. Management highlighted that implants and biopsies per surgeon are rising and that biopsy-to-implant pull-through has improved, particularly in newer territories, suggesting more productive and efficient commercial coverage.

MACI Arthro Early Clinical Signals

Management spotlighted early clinical signals for MACI Arthro, noting an investigator case series that reported reduced post-operative pain, better range of motion and faster progression to full weight bearing. Initial data have been accepted for publication, and the company has begun collecting registry data, aiming to build a stronger evidence base to support broader use.

Operational Milestone and International Pathway

Vericel secured FDA approval to commercially manufacture MACI at its new Burlington facility, expanding capacity and de-risking supply as volumes grow. The new plant also lays the groundwork for a planned marketing application in the U.K. later in 2026, with a potential U.K. launch in 2027 to open an international growth channel.

Raised Full-Year Guidance

On the back of the strong start, management lifted full-year 2026 revenue guidance by $10 million to a range of $326 million to $336 million, implying roughly 20% growth at the midpoint. MACI revenue is now expected to reach $282 million to $288 million and Burn Care $44 million to $48 million, reflecting sustained demand and the anticipated contribution from NexoBrid procurement.

BARDA Revenue Timing and Uncertainty

Executives stressed that while the BARDA framework is sizable at up to $197 million, only the $35 million base portion is currently contracted and the remainder depends on future options. The planned $5 million to $6 million of NexoBrid procurement revenue in the second half of 2026 will roll in gradually, with additional procurement, development and formulation work unfolding over multiple years.

Dependence on Biopsy-to-Implant Conversion

Management reiterated that maintaining strong biopsy-to-implant conversion is critical to sustaining MACI growth, describing current conversion as stable but not guaranteed. They flagged this metric as both a potential upside driver if trends improve and a key risk if the relationship between biopsies and implants deteriorates over time.

Investment-Driven Margin Variability

The company cautioned that near-term margins will reflect incremental costs tied to the Burlington facility, sales force expansion and enhanced MACI ankle clinical trial and life-cycle spending. For the second quarter, Vericel is guiding to around a 72% gross margin and an 18% adjusted EBITDA margin, below full-year targets but framed as temporary as the investments scale.

MACI Arthro Evidence and Adoption Lag

MACI Arthro’s approval was based on human factors rather than large outcome trials, and management acknowledged that broader adoption and payer coverage will depend on prospective and peer-reviewed data. While early results are encouraging, the company expects a lag as longer-term registry and outcomes evidence accumulates to support expanded clinical use.

Macro Risks and Market Uncertainties

Analysts pressed management on potential macro headwinds, including orthopedic procedure trends and evolving payer or access dynamics that could influence volumes. Vericel has not assumed a broad procedure slowdown in its guidance but conceded that external factors such as policy shifts and benefit changes remain important uncertainties to monitor.

Competitive and Segmentation Landscape

On competition, management downplayed direct overlap between MACI and Agili‑C, noting that the rival product is aimed more at older osteoarthritis patients rather than MACI’s current target cohort. Even so, Vericel plans to closely track evolving segmentation to ensure MACI maintains its position as the preferred option in its core patient population.

Forward-Looking Guidance and Outlook

Looking ahead, Vericel expects about $62.5 million to $63.5 million in Q2 MACI revenue and $9 million to $10 million in Burn Care revenue, with BARDA-driven NexoBrid procurement revenue starting in the back half of 2026. Management reaffirmed full-year targets of roughly 75% gross margin and a 27% adjusted EBITDA margin, along with continued strong free cash flow, signaling confidence that high growth and profitability can coexist.

Vericel’s earnings call painted the picture of a company executing well on multiple fronts, with MACI firing, Burn Care accelerating and operational upgrades supporting future expansion. While BARDA timing, conversion dynamics and macro factors introduce some uncertainty, the raised guidance and stronger balance sheet suggest that, for now, momentum is firmly on Vericel’s side.